Sugi Predict

Sugi Predict / Compounds / SCHEMBL202448

SCHEMBL202448

SCHEMBL202448

O=C(O)c1cc(Cl)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.61
▸ KDM4E B2RXH2 4/20 0.61
▸ MAPT P10636 2/20 0.61
▸ KDM4C Q9H3R0 2/20 0.61
▸ KDM6B O15054 1/20 0.61
▸ TET3 O43151 1/20 0.61
▸ KDM4A O75164 1/20 0.61
▸ BBOX1 O75936 1/20 0.61
▸ KDM5A P29375 1/20 0.61
▸ KDM5C P41229 1/20 0.61
▸ ASPH Q12797 1/20 0.61
▸ KDM4D Q6B0I6 1/20 0.61
▸ TET2 Q6N021 1/20 0.61
▸ ALKBH5 Q6P6C2 1/20 0.61
▸ KDM7A Q6ZMT4 1/20 0.61
▸ KDM8 Q8N371 1/20 0.61
▸ TET1 Q8NFU7 1/20 0.61
▸ EGLN2 Q96KS0 1/20 0.61
▸ FTO Q9C0B1 1/20 0.61
▸ EGLN1 Q9GZT9 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31151693 1.00 ALDH1A1 (0.61) ALDH1A1KDM4EMAPTKDM4CKDM6B
Hydrochloric Acid SCHEMBL27576045 0.98 ALDH1A1 (0.59) ALDH1A1KDM4EMAPTKDM4CKDM6B
Hydrochloric Acid SCHEMBL1682029 0.98 ALDH1A1 (0.59) ALDH1A1KDM4EMAPTKDM4CKDM6B
SCHEMBL29026601 0.98 ALDH1A1 (0.59) ALDH1A1KDM4EMAPTKDM4CKDM6B
SCHEMBL9440140 0.98 ALDH1A1 (0.59) ALDH1A1KDM4EMAPTKDM4CKDM6B
SCHEMBL6386124 0.88 KDM4C (0.54) ALDH1A1KDM4EMAPTKDM4CKDM6B
SCHEMBL27715023 0.84 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTKDM4CKDM6B
SCHEMBL31607215 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTKDM4CKDM6B
SCHEMBL177940 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTKDM4CKDM6B
SCHEMBL1938390 0.81 KMO (0.65) ALDH1A1KDM4EMAPTKDM4CKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119241427-A Method for comprehensively and efficiently synthesizing anticancer drug regorafenib 董帅圻 2025-01-03 — — CN claimed
CN-118465026-B In-situ electrochemical sensor for detecting aluminum ions in water body and preparation method thereof 宁波大学 2024-09-17 — — CN claimed
CN-118465026-A In-situ electrochemical sensor for detecting aluminum ions in water body and preparation method thereof 宁波大学 2024-08-09 — — CN claimed
CN-117624129-A Synthesis method of RAF265 inhibitor 上海图芃生物科技有限公司 2024-03-01 — — CN claimed
CN-114957111-B Preparation method of N-methyl-4-chloropyridine-2-formamide 扬州市普林斯医药科技有限公司 2024-02-09 — — CN claimed
CN-117247372-A Preparation method of oxindole compound 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) 2023-12-19 — — CN claimed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US claimed
CN-116375636-A Novel method for synthesizing 4-fluoropyridine-2-carbonitrile 浙江工业大学 2023-07-04 — — CN claimed
CN-110229099-B Method for preparing sorafenib key intermediate 连云港恒运药业有限公司 2023-02-21 — — CN claimed
CN-114957111-A Preparation method of N-methyl-4-chloropyridine-2-formamide 扬州市普林斯医药科技有限公司 2022-08-30 — — CN claimed
WO-2008013334-A1 DEFORMYLASE INHIBITOR, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION COMPRISING THE SAME PROMEDITECH INC. (KR) 2008-01-31 — — WO claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 — — US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 — — WO claimed
CN-1798736-A Novel quinoline, tetrahydroquinazoline and pyrimidine derivatives and methods of treatment related to their use ARENA PHARM INC (JP) 2006-07-05 — — CN claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 — — US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 — — WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 — — EP claimed
EP-0244167-B1 IMPROVED PROCESS FOR PREPARING POLY (ARYL ETHERS) AND POLY (ARYL ETHER KETONES) AMOCO CORPORATION (US) 1990-04-04 — — EP claimed
US-4748227-A Process for preparing poly(aryl ether)ketones using a sodium carbonate/organic acid salt catalyst AMOCO CORPORATION (US) 1988-05-31 — — US claimed
EP-0244167-A1 Improved process for preparing poly (aryl ethers) and poly (aryl ether ketones) AMOCO CORPORATION (US) 1987-11-04 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 ALDH1A1 2036/4885KDM4E 1190/4885MAPT 517/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R ALDH1A1 440/4885KDM4E 1864/4885MAPT 387/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 ALDH1A1 2379/4885KDM4E 1393/4885MAPT 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.